One of my concerns about the data is that it is a mix of NCI (61) and non-NCI centers (17). I am convinced from my own personal knowledge of the NCI centers, that if you looked solely at the NCI centers—this diversity data would be significantly worse. I think the survey data is skewed by the inclusion of non-NCI centers and if we looked solely at those, there would be far less diversity in race/ethnicity and sex among directors/associate directors.
Diversity, inclusion, and equity are important issues, not only to our nation's cancer centers, but to our nation as a whole. To embody these values, we must work to close gaps in cancer research and care.
How diverse are the upper rungs of leadership at America’s academic cancer centers?
Women in oncology who face gender bias know what not to do: seek help from their institutions.
The National Cancer Institute approved the following clinical research studies last month.
FDA has granted Rare Pediatric Disease Designation for IVT-8086 for the treatment of Osteosarcoma.
Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, has entered into a clinical trial collaboration with Merck & Co., Inc., through a subsidiary.
Researchers affiliated with the Cancer Center at Illinois discovered a novel small molecule compound that is now the subject of a new global licensing agreement between the pharmaceutical company Bayer AG and the cancer drug development company Systems Oncology LLC.
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and US Oncology Research, one of the largest community-based oncology site management organizations in the U.S., announced a collaboration to utilize the US Oncology Research Selected Trials for Accelerated Rollout (STAR) program for patient enrollment in the registration-enabling Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion.
An international team led by clinician-scientists at UPMC and the University of Pittsburgh School of Medicine have pooled data from 121 hospitals in eight countries to find that inexpensive, widely available steroids improve the odds that very sick COVID-19 patients will survive the illness.
